成人型弥漫性IDH突变型2级星形细胞瘤替莫唑胺为基础放化疗的长期治疗结局
103例组织学证实的2级星形细胞瘤患者接受放疗(50.4-54 Gy,1.8 Gy/次)及辅助替莫唑胺最多12周期,52例在肿瘤进展时放疗、51例术后早期放疗。中位随访9.0年,中位无进展生存期9年、总生存期11.8年;早期治疗组中位无进展生存期10.6年优于延迟治疗组6年(HR 0.30),但总生存期无显著差异。
要点
- 中位随访9.0年,中位无进展生存期9年(95%CI 6.6-10.3),中位总生存期11.8年(95%CI 9.3-13.4)。
- 早期治疗组中位无进展生存期10.6年 vs 延迟治疗组6年(HR 0.30;95%CI 0.16-0.59;p=0.0005)。
- 两组总生存期无显著差异(12.8年 vs 10.4年;HR 0.64;95%CI 0.33-1.25;p=0.23)。
核心结论
- 以替莫唑胺为基础的放化疗与2级IDH突变型星形细胞瘤患者的生存获益相关。
- 对于接受广泛切除的年轻患者,放化疗可延迟至肿瘤进展时进行;高危患者应推荐早期治疗。
研究设计与样本
- 回顾性分析103例组织学证实的2级星形细胞瘤成人患者,接受放疗50.4-54 Gy(1.8 Gy/次)及辅助替莫唑胺最多12周期。
- 52例在肿瘤进展时接受放疗,51例在术后早期因存在至少一项高危特征(年龄>40岁、术前肿瘤大小>5 cm、术后大量残留肿瘤、肿瘤跨越中线或存在神经系统症状)接受放疗。
主要发现
- 中位随访9.0年(范围1.3-15年),中位无进展生存期9年(95%CI 6.6-10.3),中位总生存期11.8年(95%CI 9.3-13.4)。
- 早期治疗组中位无进展生存期10.6年 vs 延迟治疗组6年(HR 0.30;95%CI 0.16-0.59;p=0.0005)。
- 两组总生存期无显著差异(12.8年 vs 10.4年;HR 0.64;95%CI 0.33-1.25;p=0.23)。
- 切除范围、KPS和微小残留病灶与总生存期相关,术后肿瘤≤1 cc是最强的独立预测因素(HR 0.27;95%CI 0.08-0.87;p=0.01)。
临床怎么用
- 作者认为,对于接受广泛切除的年轻患者,放化疗可延迟至肿瘤进展时进行;高危患者应推荐早期治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To report the long-term outcomes in adult patients with grade 2 IDH-mutant astrocytoma treated with temozolomide (TMZ)-based chemoradiation. METHODS: One hundred and three patients with histologically proven grade 2 astrocytoma received radiation therapy (RT), 50.4-54 Gy in 1.8 Gy fractions, and adjuvant TMZ up to 12 cycles. Fifty-two patients received RT at the time of tumor progression and 51 in the early postoperative period for the presence of at least one high-risk feature (age > 40 years, preoperative tumor size > 5 cm, large postoperative residual tumor, tumor crossing the midline, or presence of neurological symptoms). Overall survival (OS) and progression-free survival (PFS) were calculated from the time of diagnosis. RESULTS: With a median follow-up time of 9.0 years (range, 1.3-15 years), median PFS and OS times were 9 years (95%CI, 6.6-10.3) and 11.8 years (95%CI, 9.3-13.4), respectively. Median PFS was 10.6 years in the early treatment group and 6 years in delayed treatment group (hazard ratio (HR) 0.30; 95%CI 0.16-0.59; p = 0.0005); however, OS was not significantly different between groups (12.8 vs. 10.4 years; HR 0.64; 95%CI 0.33-1.25; p = 0.23). Extent of resection, KPS, and small residual disease were associated with OS, with postoperative tumor ≤ 1 cc that emerged as the strongest independent predictor (HR: 0.27; 95%CI 0.08-0.87; p = 0.01). CONCLUSIONS: TMZ-based chemoradiation is associated with survival benefit in patients with grade 2 IDH-mutant astrocytoma. For this group of patients, chemoradiation can be deferred until time of progression in younger patients receiving extensive resection, while early treatment should be recommended in high-risk patients.
引用
- Minniti G, Paolini S, Antonelli M, et al. Long-term treatment outcomes of temozolomide-based chemoradiation in patients with adult-type diffuse IDH-mutant grade 2 astrocytoma. J Neurooncol. 2023. PMID: 37665475. doi:10.1007/s11060-023-04418-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。